drugset
drugset / Trial / NCT04560660

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

NCT04560660 ↗

Phase 2 Completed 75 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.

Timeline

Start
2021-03-09
Primary completion
2025-07-01
Completion
2025-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous

Indications

post-traumatic stress disorder